MRNA Earnings: The Must-Know Verdict — Buy, Sell, or Hold?
Moderna (MRNA): Should You Buy, Sell, or Hold After Q2 Earnings?
TL;DR: Moderna’s stock has jumped 44% in six months, but analysts at StockStory warn the company’s fundamentals are deteriorating. They recommend looking elsewhere for better investment opportunities.
The Recent Rally: What Happened?
Moderna has had a fantastic six months — shares have skyrocketed 44.2%, reaching $63.36 per share. This surge came after solid quarterly results, leaving many investors wondering: Is now the time to buy, or should I be cautious?
Important Point: A rising stock price doesn’t always mean a healthy business. It’s important to look under the hood at the actual numbers.
Why Analysts Think Moderna May Underperform
Despite the recent price jump, StockStory analysts have low confidence in Moderna’s long-term prospects. Here are the three main reasons:
1. Revenue Is Spiraling Downward
- 5-year annual revenue decline: -20.5%
- This means sales have been shrinking consistently over the long term
- A healthy business typically grows revenue over time, not shrinks
- Analyst take: "This signals it’s a low-quality business."
Visual: The quarterly revenue chart shows a clear downward trend over the past five years.
2. Earnings Per Share (EPS) Is Also Falling
- 5-year annual EPS decline: -24.5% (worse than revenue!)
- What is EPS? Earnings Per Share = Company Profit ÷ Number of Shares
- When EPS falls faster than revenue, it means the company can’t control its costs as sales drop
- Analyst take: "Fixed cost base made it difficult to adjust to shrinking demand."
Visual: The trailing 12-month EPS (Non-GAAP) chart confirms the steady decline.
3. Free Cash Flow Margin Has Collapsed
- 5-year margin drop: 95.9 percentage points
- Current trailing 12-month free cash flow margin: -55.8%
- What is Free Cash Flow? Cash a company generates after paying for operations and investments — money it can actually use to pay bills, invest, or return to shareholders
- Why it matters: "Cash is king — you can’t pay bills with accounting profits."
- A negative margin means Moderna is burning cash, not generating it
Visual: The free cash flow margin chart shows a dramatic plunge into negative territory.
Final Verdict: What Should You Do?
| Factor | Status |
|---|---|
| Current Stock Price | $63.36 |
| Forward Price-to-Sales Ratio | 12.3× (high) |
| Expected Profitability (Next 12 Months) | Expected to lose money |
| Analyst Recommendation | Avoid / Look Elsewhere |
Key Insight: The market is pricing Moderna as if it will grow, but the business is expected to lose money in the near future. The upside is limited, while the downside risk is high.
Better Alternative Suggested
Analysts recommend considering one of their all-time favorite software stocks instead — a company with stronger fundamentals, consistent growth, and better cash generation.
Check out the full breakdown from expert analysts (free): StockStory Analysis
Summary
- Stock up 44% in 6 months → but driven by short-term optimism
- Revenue falling 20.5%/year for 5 years
- EPS falling 24.5%/year — costs not adjusting to lower sales
- Free cash flow margin at -55.8% — burning cash heavily
- Valuation high (12.3× sales) for a money-losing business
- Bottom line: Avoid MRNA; better opportunities exist
FAQ: Your Questions Answered
1. What does "forward price-to-sales ratio of 12.3×" mean?
It means investors are paying $12.30 for every $1 of expected sales over the next year. That’s very high — especially for a company expected to lose money.
2. Why is free cash flow more important than net income?
Net income includes accounting adjustments (like depreciation). Free cash flow shows actual cash the business generates — what it can use to pay debt, fund growth, or pay dividends.
3. Can Moderna turn things around?
Possibly — if new products (like flu or RSV vaccines) succeed. But right now, the trend is negative, and the stock price already reflects optimism.
4. What does "Non-GAAP EPS" mean?
GAAP = standard accounting rules. Non-GAAP = adjusted earnings (excluding one-time items). Companies use it to show "core" profitability, but it can hide real problems.
5. Should I sell if I already own MRNA?
This article isn’t personalized financial advice. But if you own it, review your reasons: Are you betting on a turnaround? Or just riding momentum? Consider your risk tolerance.
Disclaimer: This content is for educational purposes only and not investment advice. Always do your own research or consult a financial advisor before making investment decisions.